About Pulmonx
Pulmonx is a company based in Redwood City (United States) founded in 1998.. Pulmonx has raised $280.91 million across 15 funding rounds from investors including Canadian Imperial Bank of Commerce, Kleiner Perkins and RTW Investments. The company has 291 employees as of December 31, 2024. Pulmonx has completed 2 acquisitions, including Aeris Therapeutics and Emphasys Medical. Pulmonx offers products and services including Zephyr Valves, Chartis System, and StratX Reports. Pulmonx operates in a competitive market with competitors including Neurent Medical, Gradient Denervation Technologies, Spiration, Uptake Medical and Emphasys Medical, among others.
- Headquarter Redwood City, United States
- Employees 291 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Pulmonx Corporation
-
Annual Revenue
$83.79 M22.01as on Dec 31, 2024
-
Net Profit
$-56.39 M7.31as on Dec 31, 2024
-
EBITDA
$-54.39 M9.32as on Dec 31, 2024
-
Total Equity Funding
$280.91 M (USD)
in 15 rounds
-
Latest Funding Round
$66 M (USD), Series D
May 05, 2020
-
Investors
Canadian Imperial Bank of Commerce
& 15 more
-
Employee Count
291
as on Dec 31, 2024
-
Investments & Acquisitions
Aeris Therapeutics
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Pulmonx
Pulmonx is a publicly listed company on the NASDAQ with ticker symbol LUNG in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Pulmonx
Pulmonx offers a comprehensive portfolio of products and services, including Zephyr Valves, Chartis System, and StratX Reports. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Device for treating severe COPD by reducing hyperinflation.
System for assessing patients' pulmonary function.
Reports for evaluating CT scans in COPD treatment.
Unlock access to complete
Unlock access to complete
Software Development Team
30 people
Leadership Team
23 people
Sales and Marketing
19 people
Finance and Accounting
8 people
Legal and Compliance
5 people
Operations Team
3 people
Senior Team
3 people
Human Resources and Administration
3 people
Unlock access to complete
Funding Insights of Pulmonx
Pulmonx has successfully raised a total of $280.91M across 15 strategic funding rounds. The most recent funding activity was a Series D round of $66 million completed in May 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 15
- Last Round Series D — $66.0M
-
First Round
First Round
(01 Dec 2003)
- Investors Count 16
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2020 | Amount | Debt – Conventional - Pulmonx | Valuation |
investors |
|
| May, 2020 | Amount | Series D - Pulmonx | Valuation | Ally Bridge Group | |
| Apr, 2019 | Amount | Series D - Pulmonx | Valuation | Ally Bridge Group |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Pulmonx
Pulmonx has secured backing from 16 investors, including institutional and venture fund investors. Prominent investors backing the company include Canadian Imperial Bank of Commerce, Kleiner Perkins and RTW Investments. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are focused on tech and life sciences startups.
|
Founded Year | Domain | Location | |
|
Early-stage and late-stage biotech and finance companies are funded.
|
Founded Year | Domain | Location | |
|
Private equity and hedge fund investments in healthcare are managed.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Pulmonx
Pulmonx has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Aeris Therapeutics and Emphasys Medical. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Products for treating emphysema and lung diseases are developed.
|
2000 | ||||
|
Endobronchial valves for emphysema treatment are developed.
|
2000 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Pulmonx
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Pulmonx Comparisons
Competitors of Pulmonx
Pulmonx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Neurent Medical, Gradient Denervation Technologies, Spiration, Uptake Medical and Emphasys Medical, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Smart devices for minimally invasive rhinitis treatment are developed.
|
|
| domain | founded_year | HQ Location |
Endovascular catheter-based technology for pulmonary hypertension treatment is provided.
|
|
| domain | founded_year | HQ Location |
IntraBronchial Valve to treat lung disease
|
|
| domain | founded_year | HQ Location |
Targeted vapor therapy is developed for endoscopic lung volume reduction.
|
|
| domain | founded_year | HQ Location |
Endobronchial valves for emphysema treatment are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Pulmonx
Frequently Asked Questions about Pulmonx
When was Pulmonx founded?
Pulmonx was founded in 1998 and raised its 1st funding round 5 years after it was founded.
Where is Pulmonx located?
Pulmonx is headquartered in Redwood City, United States. It is registered at Redwood City, California, United States.
Who is the current CEO of Pulmonx?
Glen French is the current CEO of Pulmonx.
Is Pulmonx a funded company?
Pulmonx is a funded company, having raised a total of $280.91M across 15 funding rounds to date. The company's 1st funding round was a Series D of $65.13M, raised on Dec 01, 2003.
How many employees does Pulmonx have?
As of Dec 31, 2024, the latest employee count at Pulmonx is 291.
What is the annual revenue of Pulmonx?
Annual revenue of Pulmonx is $83.79M as on Dec 31, 2024.
What does Pulmonx do?
Pulmonx is a developer of smart devices for treating pulmonary diseases. The company is focused on developing and marketing minimally-invasive medical devices and technologies for the diagnosis and treatment of pulmonary disorders. It is currently engaged in the design, development, and manufacture of products that will improve the effectiveness and benefits of endoscopic lung volume reduction (ELVR) for patients with severe emphysema. The companys Zephyr Endobronchial Valve (EBV) therapy involves placing small one-way valves in the lung to prevent air from entering the most diseased regions while allowing fluids and trapped air to escape. The company has a CE Mark for the Zephyr Endobronchial Valves and has submitted a CE mark application for the Chartis System.
Who are the top competitors of Pulmonx?
Pulmonx's top competitors include Neurent Medical, Gradient Denervation Technologies and Spiration.
What products or services does Pulmonx offer?
Pulmonx offers Zephyr Valves, Chartis System, and StratX Reports.
Is Pulmonx publicly traded?
Yes, Pulmonx is publicly traded on NASDAQ under the ticker symbol LUNG.
How many acquisitions has Pulmonx made?
Pulmonx has made 2 acquisitions, including Aeris Therapeutics, and Emphasys Medical.
Who are Pulmonx's investors?
Pulmonx has 16 investors. Key investors include Canadian Imperial Bank of Commerce, Kleiner Perkins, RTW Investments, Driehaus, and Oxford Finance.
What is Pulmonx's ticker symbol?
The ticker symbol of Pulmonx is LUNG on NASDAQ.